Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Steris Plc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Steris Plc (STE31) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2022
Competitors Tracked
5
Publicly traded peers
Peer Group Market Share
32.51 %
vs 49.74 % a year ago
Revenue Growth Y/Y
-7.99 %
Peers: 89.03 %
Net Margin
11.09 %
Peers: 10.02 %

Key Findings: Steris Plc vs Its Competitors

  • TTM: Trailing 12-month revenue of 4,466M vs 11,524M combined for tracked competitors (27.9% combined share).
  • Trending: Latest-quarter revenue run-rate is holding steady (-0.4% annualized vs trailing 12 months), vs decelerating (-19.8%) for its tracked peer group.
  • Growth: Steris Plc generated -8.0% revenue growth year over year in Q3 2022, vs 89.0% for its tracked competitors combined.
  • Profitability: Its 11.1% net margin compares with 10.0% for the peer group.
  • Peer revenue share: Steris Plc accounted for 32.5% of combined revenue among its tracked peer group, down from 49.7% a year earlier.
  • Peer differentiation: Revenue per employee of $0.32M compares with $0.31M for the peer group (1.0x).

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

STE31 Sales vs. its Competitors, Q3 2022

Steris Plc reported revenue contraction of 7.99 % year on year in Q3 2022, below its competitors' combined revenue growth of 89.03 %.

With a net margin of 11.09 %, Steris Plc achieved higher profitability than its competitors (10.02 %).

Steris Plc generated 32.51 % of the combined sales of its peer group, down from 49.74 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/STE31/competitors
https://api.csimarket.com/api/v1/companies/STE31/relationships
https://api.csimarket.com/api/v1/companies/STE31/similar
Programmatic access for models, analytics, and integration workflows.

Steris Plc vs. its Competitors, Q3 2022

Revenue growth, year on year

Steris Plc -8.0 %
Competitors combined +89.0 %

Net income growth, year on year

Steris Plc -13.8 %
Competitors combined +156.1 %

Net margin

Steris Plc +11.1 %
Competitors combined +10.0 %

Revenue run-rate vs trailing 12 months

Steris Plc -0.4 %
Competitors combined -19.8 %

TTM net margin

Steris Plc -0.7 %
Competitors combined +9.7 %

TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Steris Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.

Competitor Financial Benchmarking - TTM Commercial

TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Steris Plc and its 4 competitor groupings. Available under Commercial License.

Entity TTM Revenue Latest Q ×4 Rev Run-rate vs TTM TTM Net Income TTM Net Margin
Steris Plc $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitors combined $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
High-Confidence Competitors (7) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Similar Growth & Profitability (7) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitor Financial Benchmarking

TTM revenue, run-rate and net margin benchmarking across Steris Plc's competitor groups requires a Commercial License.

For context: the Medical Equipment & Supplies industry grew revenue 15.1% year over year, combined, vs -8.0% for Steris Plc. Steris Plc's share of combined industry revenue moved from 1.19% to 0.95%, a loss of 0.24 percentage points.

Steris Plc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Steris Plc Yes Yes No No
Competitors combined (5) 50% 80% 20% 20%
High-Confidence Competitors (9) 78% 89% 33% 11%
Similar Growth & Profitability (8) 100.00 % (8 of 8) 100.00 % (8 of 8) 37.50 % (3 of 8) 12.50 % (1 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q3 2022

32.5%market share
  • Steris Plc32.5%
  • Competitors combined67.5%

Share of combined quarterly revenue of Steris Plc and its 5 tracked competitors.

See Steris Plc's full market share breakdown »

STE31 Stock Performance relative to its Competitors

STE31 Competitors (weighted) Percent change over the selected range

Steris Plc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
25%beat U.S.A. 500
Competitors Combined
(1 of 4)
20%beat U.S.A. 500
High-Confidence
(1 of 5)
14.3%beat U.S.A. 500
Similar Growth & Profitability
(1 of 7)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Steris Plc - -
Competitors combined (4) 40.4% 63.2%
High-Confidence Competitors (5) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (7) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Steris Plc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

STE31 Stock Performance relative to High-Confidence Competitors

STE31 High-Confidence Competitors (equal-weighted, 9) Percent change over the selected range

STE31 Stock Performance relative to Similar Growth & Profitability Competitors

STE31 Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#CompetitorTTM Share Price Returnvs U.S.A. 500
1 Tomi Environmental Solutions Inc 282.9% Outperformed
2 Aptargroup inc 282.9% Outperformed
3 Integra Lifesciences Holdings Corp 282.9% Outperformed
4 Steris Plc 282.9% Outperformed
Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Steris Plc's best-performing tracked competitors requires a Commercial License.

Source: CSIMarket API, trailing 12 months.

Publicly Traded Peers of Steris Plc

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Steris Plc - 4,465.70 -29.10 14,000
Steris Plc 21,976.54 5,935.90 785.10 18,179
Aptargroup inc 7,994.54 3,933.24 362.88 14,000
Integra Lifesciences Holdings Corp 1,032.60 1,647.67 -7.24 4,427
Tomi Environmental Solutions Inc 11.17 6.93 -3.45 20
Motus Gi Holdings Inc 0.00 0.33 -16.10 31
SUBTOTAL 31,014.85 15,989.77 1,092.09 50,657

Sources: Steris Plc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Steris Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Steris Plc's Competitors Named by the Company

Competitive relationships identified from Steris Plc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Crothall Company report 85% 2022 to 2026 3
Olympus Company report 85% 2022 to 2026 3
Ruhof Company report 85% 2022 to 2026 3
Stryker Company report 85% 2022 to 2026 3
BBraun Company report 85% 2022 to 2026 3
Fortive Company report 85% 2022 to 2026 3
Boston Scientific Company report 85% 2022 to 2026 3
Ecolab Company report 85% 2022 to 2026 3
Karl Storz Company report 85% 2022 to 2026 3
Skytron Company report 85% 2022 to 2026 3
Belimed Company report 85% 2022 to 2026 3
Contec Company report 85% 2022 to 2026 3
Getinge Company report 85% 2022 to 2026 3
Stilmas Company report 85% 2022 to 2026 3
Baxter Company report 85% 2022 to 2026 3
Fedegari Company report 85% 2022 to 2026 3
Pentax Company report 85% 2022 to 2026 3
SteelCo Company report 85% 2022 to 2026 3
Wassenburg Company report 85% 2022 to 2026 3
Agiliti Company report 85% 2022 to 2026 3
Berendsen plc Company report 85% 2022 to 2026 3
Hill-Rom Company report 85% 2022 to 2026 3
CleanLease (Clean Lease Fortex) Company report 85% 2022 to 2026 3
Mobile Company report 85% 2022 to 2026 3
Rentex Awé Company report 85% 2022 to 2026 3
Sterilog Limited Company report 85% 2022 to 2026 3
Owens & Minor Company report 85% 2022 to 2026 3
Techniplast Company report 85% 2022 to 2026 3
Northfield Company report 85% 2022 to 2026 3
Rentex Floren Company report 85% 2022 to 2026 3
Cantel Medical Company report 85% 2022 to 2026 3
MECO Company report 85% 2022 to 2026 3
Tomi Environmental Solutions Inc Company report 85% 2022 to 2026 3
Motus Gi Holdings Inc Company report 85% 2022 to 2026 3
Aptargroup inc Company report 85% 2022 to 2026 3
Steris Plc Company report 85% 2022 to 2026 3
Integra Lifesciences Holdings Corp Company report 85% 2022 to 2026 3
Danaher Corporation Company report 85% 2022 to 2026 3
Sotera Health Company Company report 85% 2022 to 2026 3
Thermo Fisher Scientific Inc Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Steris Plc's named competitors require a Commercial License.

Methodology: relationships are extracted from Steris Plc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Steris Plc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Steris Plc Healthcare 70.23 % Applied Sterilization Technologies 19.94 % Life Science 9.83 %
Aptargroup inc Pharma 44.65 % Beauty 36.77 % Closures 19.73 %
Integra Lifesciences Holdings Corp Specialty Surgery 73.85 % Tissue Reconstruction 26.15 % -

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Steris Plc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Steris Plc - 318,979 -2,078
Steris Plc 21,977 326,525 43,187
Aptargroup inc 7,995 280,946 25,920
Integra Lifesciences Holdings Corp 1,033 372,186 -1,636
Tomi Environmental Solutions Inc 11 346,470 -172,442
Motus Gi Holdings Inc 0 10,548 -519,419
PEERS TOTAL 31,015 314,376 30,586

Steris Plc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.
Company Largest Market 2nd Market 3rd Market
Steris Plc United States 73.06 % Non-US 25.00 % Ireland 1.94 %
Aptargroup inc Europe 50.76 % North America 28.45 % Asia 12.51 %
Integra Lifesciences Holdings Corp United States 73.34 % Asia Pacific 11.63 % Europe 10.17 %
Tomi Environmental Solutions Inc International 15.09 % - -

Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Steris Plc's Strategic Group Map

Every company in Steris Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Steris Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.

Revenue Growth (TTM, %)Operating Margin (%)SYKBSXSTESteris PlcMDTSTVNSTJUFPTZBH

Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.

Steris Plc's Industry Attractiveness & Competitive Strength

A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.

High Strength
Medium Strength
Low Strength
High Attractiveness
Invest / Grow
Invest / Grow
Selective
Medium Attractiveness
Invest / Grow
Selective Steris Plc
Harvest
Low Attractiveness
Selective
Harvest
Harvest / Divest

Steris Plc falls in the Medium attractiveness / Medium strength cell: Selective.

Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.

Steris Plc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

No rule matched.

Opportunities

No rule matched.

Threats

  • Tracked peer group's revenue run-rate is broadly decelerating (-19.8% annualized).

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Steris Plc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Steris Plc 0.16 2.07 0.48 0.40
Steris Plc 0.15 2.15 0.27 0.57
Aptargroup inc 0.22 1.50 0.61 0.76
Integra Lifesciences Holdings Corp 0.61 3.12 1.87 0.46
Tomi Environmental Solutions Inc 0.02 1.42 2.84 0.90
Motus Gi Holdings Inc 1.55 1.80 6.79 0.04

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Steris Plc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Steris PlcQ4 2022-8.0 %+2.0 %-13.8 %-
Steris PlcQ1 2026+7.3 %+6.2 %+50.8 %+13.4 %
Aptargroup incQ2 2026+6.3 %+4.4 %-21.2 %+20.9 %
Integra Lifesciences Holdings CorpQ2 2026+0.8 %+6.8 %--
Tomi Environmental Solutions Inc Q2 2026+117.9 %+35.8 %--
Motus Gi Holdings Inc Q1 2024+14.3 %+0.0 %--
PEERS TOTAL+1.9 %+4.7 %--

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Steris Plc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Steris PlcQ4 2022-5.5 %+4.2 %-16.1 %+7.4 %
Steris PlcQ1 2026+6.2 %+6.0 %--
Aptargroup incQ2 2026+23.6 %+17.4 %-10.9 %-12.3 %
Integra Lifesciences Holdings CorpQ2 2026-3.5 %+13.8 %-38.9 %-17.1 %
Tomi Environmental Solutions Inc Q2 2026+143.4 %+4.8 %-78.9 %+166.1 %
Motus Gi Holdings Inc Q1 2024+33.3 %-36.8 %--

Steris Plc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Steris Plc---5.694.07
Steris Plc7.53%7.97%11.29%5.895.27
Aptargroup inc7.05%8.83%13.48%4.725.68
Integra Lifesciences Holdings Corp---6.141.59
Tomi Environmental Solutions Inc ---7.000.69
Motus Gi Holdings Inc ---3.580.14

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Steris Plc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Steris Plc-----
Steris Plc28.113.701.0182.033.05
Aptargroup inc22.602.0341.28261.273.02
Integra Lifesciences Holdings Corp-0.63--0.99
Tomi Environmental Solutions Inc -1.61-10.627.82
Motus Gi Holdings Inc -0.01--0.00
PEERS AVERAGE28.401.9447.941.78

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API Connect Your AI